OliX Pharmaceuticals Inc
KOSDAQ:226950
OliX Pharmaceuticals Inc
OliX Pharmaceuticals, Inc. engages in the research and development of treatments and the manufacture and sale of new drugs. The company is headquartered in Suwon, Gyeonggi-Do and currently employs 72 full-time employees. The company went IPO on 2018-07-18. The Company’s product profile consists of OLX101, OLX102, OLX103, OLX104, OLX201, OLX301, OLX401 and others. These products are used for the treatment of hypertrophic scars and keloids, atopic dermatitis, androgenic alopecia, diabetic ulcer, age-related macular degeneration (AMD), idiopathic pulmonary fibrosis, neuropathic pain, liver fibrosis. In addition, these products are applied for skin brightening, anti-wrinkle and others. The firm operates its business within domestic market and to overseas markets.
OliX Pharmaceuticals, Inc. engages in the research and development of treatments and the manufacture and sale of new drugs. The company is headquartered in Suwon, Gyeonggi-Do and currently employs 72 full-time employees. The company went IPO on 2018-07-18. The Company’s product profile consists of OLX101, OLX102, OLX103, OLX104, OLX201, OLX301, OLX401 and others. These products are used for the treatment of hypertrophic scars and keloids, atopic dermatitis, androgenic alopecia, diabetic ulcer, age-related macular degeneration (AMD), idiopathic pulmonary fibrosis, neuropathic pain, liver fibrosis. In addition, these products are applied for skin brightening, anti-wrinkle and others. The firm operates its business within domestic market and to overseas markets.
